Recombinant Rat Apolipoprotein L domain-containing protein 1 (Apold1)

Advanced Research Questions

• What phenotypes are observed in Apold1 knockout models and how do they inform our understanding of Apold1 function?

Apold1 knockout (Apold1-/-) mice exhibit several distinct phenotypes that illuminate the protein's function:

These phenotypes collectively suggest that while Apold1 is dispensable for normal development, it plays crucial roles in pathological angiogenesis and vascular homeostasis .

• How does Apold1 deficiency affect arterial thrombosis, and what mechanisms are involved?

Apold1 deficiency results in a prothrombotic phenotype. In a photochemical injury model of carotid thrombosis, Apold1-/- mice exhibit:

• Significantly shorter time to occlusion (29.42 ± 2.74 min vs. 39.96 ± 3.86 min in WT mice)

• Increased tissue factor (TF) activity in carotid arteries (27.31 ± 4.55 pM/g vs. 13.48 ± 3.20 pM/g in WT)

• Enhanced platelet reactivity to collagen stimulation, with:

  • Increased maximal aggregation (68.49 ± 6.88% vs. 40.46 ± 5.93%)

  • Increased rate of aggregation (47.13 ± 12.35 %/min vs. 16.79 ± 3.5 %/min)

  • Decreased lag phase (106.6 ± 21.73 s vs. 175.5 ± 24.05 s)

Mechanistically, this prothrombotic phenotype appears to involve reduced phosphorylation of Akt in the PI3K/Akt pathway, while MAPK activation remains unaffected . Interestingly, platelet count and volume are unchanged in Apold1-/- mice, indicating that the enhanced thrombotic tendency is due to functional changes rather than platelet numbers .

• What role does Apold1 play in angiogenesis and recovery from ischemia?

Apold1 is a key regulator of angiogenesis specifically in pathological settings:

• Developmental angiogenesis: Apold1 is dispensable for normal development and does not affect postnatal retinal angiogenesis or vascular networks in adult brain and muscle .

• Pathological angiogenesis: Apold1-/- mice display:

  • Dramatic impairments in recovery and revascularization following photothrombotic stroke

  • Poor recovery after femoral artery ligation

  • Stunted growth of subcutaneous B16 melanoma tumors with smaller and poorly perfused vessels

Mechanistically, Apold1 is activated in endothelial cells upon growth factor stimulation and in hypoxic conditions. It intrinsically controls endothelial cell proliferation but not migration . This selective role in pathological angiogenesis makes Apold1 a promising candidate for clinical investigation, particularly for targeted therapies that might selectively affect pathological but not physiological angiogenesis.

• How does APOLD1 regulate endothelial cell function at the subcellular level?

APOLD1 localizes to specific subcellular compartments in endothelial cells and regulates several key functions:

• Cell junctions: APOLD1 localizes to endothelial cell contacts. Silencing of APOLD1 disrupts the cell junction-cytoskeletal interface, altering endothelial permeability .

• Weibel-Palade bodies (WPBs): APOLD1 associates with von Willebrand factor (VWF) tubules within WPBs. APOLD1 depletion leads to:

  • Reformation of WPBs into autophagosome-like organelles

  • Spontaneous release of WPB contents (VWF and angiopoietin-2) into the extracellular medium

  • Impaired autophagy flux, which is essential for regulated WPB release

These findings indicate that APOLD1 maintains endothelial homeostasis by preserving cell junction integrity and regulating the storage and release of WPB contents, which are critical for vascular function.

• What is the association between APOLD1 mutations and human disease?

A mutation in APOLD1 has been identified in a family with an inherited bleeding disorder:

• The mutation (APOLD1:p.R49*) is a dominant heterozygous nonsense variant that segregated to affected family members across three generations .

• Patients present with an atypical bleeding diathesis associated with episodic impaired microcirculation .

• The clinical profile is unusual, potentially explained by:

  • Compromised vascular integrity resulting from excess plasma angiopoietin-2

  • Locally impaired availability of VWF

This contrasts with findings in Apold1-/- mice, which show a prothrombotic phenotype with higher platelet reactivity . This apparent contradiction might reflect species-specific differences or the distinction between complete knockout versus a specific mutation that could have dominant-negative effects.

• What methodologies are optimal for producing and purifying recombinant Apold1 protein?

Based on established protocols for recombinant apolipoprotein production:

• Expression system selection:

  • E. coli systems (such as BL21 DE3) can efficiently produce rat Apold1

  • HEK293 cells are suitable for producing properly folded mammalian Apold1

• Vector design considerations:

  • pET30 expression vectors with N-terminal His-tags facilitate purification

  • The His-tag can be removed with specific proteases like IgA protease (Igase) from Neisseria gonorrhoeae, which is preferable as common proteases may cleave apolipoproteins at undesired sites

• Storage and handling:

  • Recombinant Apold1 should be stored at -20°C/-80°C upon receipt

  • For extended storage, aliquoting is necessary to avoid repeated freeze-thaw cycles

  • Working aliquots can be stored at 4°C for up to one week

• Reconstitution:

  • Lyophilized protein should be reconstituted in deionized sterile water to a concentration of 0.1-1.0 mg/mL

  • Addition of 5-50% glycerol is recommended for long-term storage at -20°C/-80°C

• What experimental applications are most suitable for recombinant Apold1 proteins and what controls should be implemented?

Recombinant Apold1 proteins are valuable tools for several experimental applications:

• Functional studies:

  • Cell culture experiments to assess effects on endothelial permeability

  • Analysis of interaction with autophagy pathways

  • Investigation of effects on platelet aggregation

• Protein-protein interaction studies:

  • Immunoprecipitation/Co-precipitation to identify binding partners

  • Pre-coupled magnetic beads can facilitate convenient and fast capture of target molecules with high specificity

• Signaling pathway analysis:

  • Examining effects on PI3K/Akt and MAPK pathways

  • Evaluating impacts on tissue factor activity

Key experimental controls should include:

• Wild-type recombinant protein as a positive control

• Structurally similar but functionally distinct proteins as negative controls

• Concentration-dependent studies to establish dose-response relationships

• Comparison with endogenous Apold1 function in appropriate cell types

• Validation of results across multiple experimental systems (in vitro and in vivo)

• How do findings from Apold1-/- mice contrast with human APOLD1 mutations, and what explains these differences?

There are notable contradictions between mouse and human Apold1/APOLD1 deficiency phenotypes:

These contradictions might be explained by:

• Species-specific differences in Apold1 function (human APOLD1 has 348 amino acids while rat Apold1 has 246 amino acids)

• Nature of the genetic alteration:

  • Complete knockout in mice vs. a specific truncating mutation (R49*) in humans

  • The R49* mutation may have dominant-negative effects rather than simple loss-of-function

• Compensatory mechanisms:

  • Different compensatory pathways may exist in mice versus humans

  • Developmental compensation in constitutive knockout models versus acute disruption in human disease

• Context-specific roles:

  • Apold1 may have different functions in different vascular beds or under different physiological stresses

  • The mutation in humans might affect specific functions while preserving others

Understanding these contrasts is crucial for translating findings from animal models to human disease implications .

Methodological Research Questions

• What are the most effective protocols for studying Apold1 function in endothelial cells?

For studying Apold1 function in endothelial cells, researchers should consider these methodological approaches:

• Gene expression manipulation:

  • siRNA-mediated APOLD1 depletion in human dermal blood endothelial cells has been successfully used to study morphology and function

  • CRISPR-Cas9 gene editing for stable knockout models

  • Overexpression studies using plasmid transfection

• Endothelial functional assays:

  • Permeability assays using fluorescent tracers

  • Cell junction integrity assessment via immunofluorescence of VE-cadherin and other junction proteins

  • Weibel-Palade body exocytosis measurements using VWF and angiopoietin-2 as markers

  • Autophagy flux assessment using LC3 conversion and p62 degradation

• Angiogenesis models:

  • In vitro: tube formation assays, scratch migration assays, spheroid sprouting assays

  • Ex vivo: aortic ring assay

  • In vivo: retinal angiogenesis, matrigel plug assay, tumor angiogenesis models

• Stress response models:

  • Hypoxia chambers to mimic ischemia

  • Growth factor stimulation (VEGF, FGF2, Angiopoietin-2)

  • Flow studies to assess mechanotransduction responses

• Localization studies:

  • Subcellular fractionation

  • Co-immunoprecipitation with junctional proteins and WPB components

  • Super-resolution microscopy to visualize precise subcellular distribution